Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

A new study suggests belly fat could increase the ... Weight loss drugs such as Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) could be crucial treatment options for patients looking to keep ...

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Last year, the medicine aced a phase 3 study in which it delayed ... including several new ones. Over the past two years, Eli Lilly has earned approval for such products as Alzheimer's disease ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... a lot of weight could put them at risk for that disease, but a new study suggests that could indeed be the case. According to a recent study ...